Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
Core Innovation
The invention relates to a conjugate comprising a carrier peptide covalently attached to a phosphorodiamidate morpholino oligomer (PMO). The PMO comprises a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid, and the covalent attachment consists of an amide bond to a carboxy-terminal glycine or proline of the carrier peptide, with an optional linker group.
The carrier peptide comprises amino acid subunits including a glycine (G) or proline (P) amino acid subunit at the carboxy terminus and contains positively charged amino acids under defined constraints. Two or more of the amino acid subunits are positively charged amino acids, and no more than seven contiguous amino acid subunits are arginine.
The disclosure further describes refinements for positively charged content, including quantitative fractions, rules on which amino acid subunits are positively charged, and structured repeating positively charged motifs. Supporting description also references PMO variants, terminal-modified PMO conjugates, and additional conjugate-related chemistry, including optional hydrophobic or hydrophilic terminal moieties and linker-containing variants.
Claims Coverage
The independent claim covers a conjugate comprising a carrier peptide and a sequence-targeting PMO, covalently attached via an amide bond to a carboxy-terminal glycine or proline, with defined constraints on positively charged amino acid subunits in the carrier peptide. Dependent claim refinements add quantitative positive-charge limits, repeating positively charged motifs, and optional hydrophobic residue constraints.
Carrier peptide covalently attached to a sequence-targeting PMO via a carboxy-terminal amide bond
A conjugate comprising a carrier peptide comprising a glycine (G) or proline (P) amino acid subunit at the carboxy terminus, a phosphorodiamidate morpholino oligomer (PMO) comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid, and a covalent attachment between the morpholino oligomer and the carrier peptide, the covalent attachment consisting of an amide bond to the carboxy-terminal glycine or proline and an optional linker group.
Positively charged carrier peptide with limited contiguous arginine
Two or more of the amino acid subunits are positively charged amino acids, and no more than seven contiguous amino acid subunits are arginine.
Minimum fraction of positively charged amino acids
At least 20% of the amino acid subunits are positively charged amino acids.
All carrier residues positively charged except terminal G or P
All amino-acid subunits are positively charged except the carboxy-terminal glycine or proline.
Repeating positively charged motif (Rd)m
The carrier peptide contains a repeating sequence of positively charged amino acids (Rd)m, where m is an integer from 2 to 12.
Rd identity restricted to arginine, histidine, or lysine
R_d is independently arginine, histidine or lysine at each occurrence.
Hydrophobic amino acid inclusion with heteroatom-per-carbon limit
The carrier peptide includes at least one hydrophobic amino acid with a substituted or unsubstituted hydrophobic side chain that has at most one heteroatom per six carbon atoms.
The claim coverage centers on a carrier peptide–PMO conjugate configured for sequence-specific binding, with covalent attachment through an amide bond to a carboxy-terminal glycine or proline and carrier peptide composition controlled by positive-charge constraints, repeating motifs, and optional hydrophobic residue limitations.
Stated Advantages
Reduce toxicity while maintaining or improving antisense performance, including protein expression inhibition and exon/splice correction.
Enhancement of antisense activity by conjugating carrier peptides.
For certain peptide terminal linker variants, similar exon skipping efficacy is achieved with an improved therapeutic window.
Documented Applications
Influenza indications.
Picornaviridae (Enterovirus/Rhinovirus).
Flaviviridae, including dengue virus.
Nidoviridae.
Filoviruses, including Ebola virus and Marburg virus.
Arenaviridae, including Old World and New World viruses listed in the document.
Respiratory syncytial virus (RSV).
Neuromuscular disease indications including Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and myotonic dystrophy type 1 and type 2.
Functional outcomes including protein expression inhibition and exon skipping.
Use of the conjugates in cell-free translation assays and splice correction translation assays to evaluate antisense-related activity.
Application context for splice correction gain of function and inhibition of viral stem-loop secondary structure via targeting base sequences, including discussion of dissociation Tm criteria.
Therapeutic/application areas discussed include antiviral classes and influenza targeting sequences.
Antiviral/therapeutic embodiments targeting nucleic acid sequence elements in viral genomes, including influenza; Picornaviridae (Enterovirus/Rhinovirus); flavivirus (including dengue via 5′/3′ cyclization sequences); nidovirus via transcriptional regulatory sequences (TRS); filoviruses including Ebola virus and Marburg virus targeting within an AUG start-site region; and arenaviruses.
An exemplary anti-RSV context, including preferred targeting of RSV L mRNA in an AUG translation start-site region and within defined windows.
Neuromuscular disease applications including Duchenne muscular dystrophy (DMD) with myostatin and exon skipping in dystrophin; spinal muscular atrophy (SMA) exon 7 inclusion concept via intron 7 targeting; and myotonic dystrophy type 1/2 (DM1/DM2) via repeat targeting of DMPK polyCUG/polyCCUG repeats.
Exon 23 skipping efficacy is assessed in MDX mice (Duchenne muscular dystrophy model), including assessment of toxicity markers including BUN, KIM-1, and clusterin.
Antibacterial antisense PMO targeting bacterial mRNAs.
Nuclear hormone receptor (GR/PR/AR) splicing modulation via morpholino-linked antisense oligomers, including modulation of ligand-binding exons.
In vivo/animal readouts including blood urea nitrogen (BUN), kidney injury markers such as clusterin (Clu), survival, and mice kidney tissue oligomer concentration.
Interested in licensing this patent?